维贝格龙(Vibegron) - 药物靶点：β3-adrenergic receptor_在研适应症：膀胱过度活动症综合征，尿频，急迫性尿失禁_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Vibegron (JAN/USAN)、KRP-114V、MK-4618

+ [8]

靶点

β3-adrenergic receptor

作用机制

β3-adrenergic receptor激动剂(β3-肾上腺素能受体激动剂)

治疗领域

泌尿生殖系统疾病

在研适应症

膀胱过度活动症综合征尿频急迫性尿失禁+ [3]

非在研适应症

内分泌系统疾病高血压肠易激综合征+ [1]

原研机构

Merck & Co., Inc.

在研机构

Urovant Sciences Ltd.

Pierre Fabre SAPierre Fabre Médicament SAS

+ [6]

非在研机构

Merck GmbH

Merck Sharp & Dohme Corp.

Merck & Co., Inc.

+ [1]

最高研发阶段批准上市

首次获批日期

日本 (2018-09-21),

膀胱过度活动症

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构

分子式C26H28N4O3

InChIKeyDJXRIQMCROIRCZ-XOEOCAAJSA-N

CAS号1190389-15-1

关联

36

项与维贝格龙相关的临床试验

NCT06438861 / Not yet recruitingN/AIIT

Exploring the Additive Effect of Vibegron to Intradetrusor OnabotulinumtoxinA in Women With Refractory Overactive Bladder

Defined by the International Continence Society (ICS) as urinary "urgency, with or without urge incontinence, usually with frequency and nocturia", overactive bladder (OAB) presents as challenging syndrome to treat. OAB is a very prevalent condition, affecting between 11.8% to 16% of the population with equal impact on women and men and growing prevalence with age. OAB is associated with a significant financial burden to both patients and the health care system with a estimated cost of US $82.6 billion in 2020. Traditionally, a stepwise approach has been taken in managing OAB; starting first with lifestyle modifications, followed by anticholinergic or beta-3-agonist medications as the second line, and lastly, intradetrusor onabotulinumtoxinA injections, percutaneous tibial nerve stimulation (PTNS), and sacral neuromodulation (SNM) as third line options. Given the limitations of this stepwise approach in patients with refractory OAB, combination therapy offers patients an increasing number of treatment options but the literature surrounding the efficacy of combination therapy is somewhat limited. A 2019 systematic review revealed there were only 32 studies in the current OAB literature that explored the role of combination therapy, and the majority of these studies examined the effect of lifestyle modifications with another intervention strategy, highlighting an untapped area of research5.
To date, there has only been a single pilot study conducted in Taiwan examining the effect of intradetrusor onabotulinumtoxinA injections with the addition of mirabegron for patients with refractory OAB. This study by Wang et al. explored the therapeutic impact of adding either an anticholinergic, solifenacin, or a beta-3 agonist, mirabegron, to intradetrusor onabotulinumtoxinA injections as compared to each other as well as patients receiving onabotulinumtoxinA alone. Ninety patients were enrolled with 30 patients allocated to the solifenacin arm, 31 to the mirabegron arm, and 29 to the control group. While the baseline data among the three arms was comparable, the percentage of OAB wet in the mirabegron plus onabotulinumtoxinA group was significantly less at 3-, 6-, 9-, and 12-month intervals than the solifenacin plus onabotulinumtoxinA and the onabotulinumtoxinA alone groups. While this pilot study reveals the potential additive benefit of a beta-3 agonist to intradetrusor onabotulinumtoxinA, no further studies have been performed to date and there are no studies regarding the additive benefit of vibegron, which has a more tolerable side effect profile and is not as limited by as many contraindications as mirabegron. If vibegron can potentiate the effect of intradetrusor onabotulinumtoxinA, this presents a new treatment strategy for OAB and could offer patients an additional line of therapy before having to pursue more invasive and costly management option of sacral neuro modulation.

开始日期2025-04-01

申办/合作机构

The University of Alabama at Birmingham

JPRN-jRCTs031240134 / RecruitingN/AIIT

ADVISR trial: ADd-on or switch to Vibegron in patients with overactive bladder InSufficiently responding to initial 4-Week antimuscarinics: A Randomized, parallel-group, multicenter study - ADVISR trial

开始日期2024-06-14

申办/合作机构-

NCT06417177 / Recruiting早期临床1期IIT

Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia

The purpose of this study is to examine hypoxic vasodilation and the role of beta-adrenergic receptors in younger premenopausal, perimenopausal, and older postmenopausal women.

开始日期2024-06-03

申办/合作机构

University of Missouri

100 项与维贝格龙相关的临床结果

登录后查看更多信息

100 项与维贝格龙相关的转化医学

登录后查看更多信息

100 项与维贝格龙相关的专利（医药）

登录后查看更多信息

109

项与维贝格龙相关的文献（医药）

2024-09-01·NEUROUROLOGY AND URODYNAMICS

Comparative analysis of real‐world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims study

Article

作者: Staskin, David ; Carrera, Adam ; Landis, Christina ; Chastek, Benjamin ; Abedinzadeh, Laleh ; Bancroft, Tim ; Kennelly, Michael ; Snyder, Daniel ; Nesheim, Jeffrey

Abstract:

Introduction:

Vibegron is a selective β3‐adrenergic receptor agonist that was approved by the US Food and Drug Administration in December 2020 for the treatment of overactive bladder in adults. This retrospective study assessed US pharmacy claims data to evaluate the real‐world adherence and persistence of vibegron compared with mirabegron and with anticholinergics.

Materials and Methods:

This analysis used the Optum Research Database to identify adults with ≥1 pharmacy claim for vibegron, mirabegron, or an anticholinergic from April 1, 2021, to August 31, 2022. Patients had ≥ 90 days of continuous commercial or Medicare medical and pharmacy coverage preindex and ≥ 60 days of continuous pharmacy coverage postindex. Two independent propensity‐score models matched patients treated with (1) vibegron versus mirabegron and (2) vibegron versus anticholinergics on key variables such as demographics and clinical characteristics, index copay, days' supply, and time of entry into analysis (index quarter). Adherence was measured by proportion of days covered (PDC) from index to the end of follow‐up and was defined as PDC ≥ 80%. Persistence was defined as days to discontinuation of index medication (first 30‐day gap) or end of follow‐up.

Results:

The matched vibegron and mirabegron cohorts included 4921 and 9842 patients, respectively, and the matched vibegron and anticholinergic cohorts included 4676 and 9352 patients, respectively. Patients receiving vibegron had greater mean PDC versus patients receiving mirabegron (0.67 vs. 0.64, respectively; p < 0.001) or anticholinergics (0.67 vs. 0.58; p < 0.001). A greater percentage of patients receiving vibegron were adherent versus those receiving mirabegron (49.0% vs. 45.1%, respectively; p < 0.001) or anticholinergics (49.1% vs. 38.5%; p < 0.001). Persistence was longer with vibegron compared with both mirabegron (median [95% CI], 171 [159–182] vs. 128 [122–137] days, respectively; p < 0.001) and anticholinergics (172 [159–183] vs. 91 [91] days; p < 0.001).

Conclusion:

In this retrospective analysis of pharmacy claims data, patients receiving vibegron exhibited significantly higher adherence and demonstrated longer persistence in comparison to matched patient cohorts receiving either mirabegron or anticholinergics.

2024-08-01·JOURNAL OF UROLOGY

Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial

Article

作者: Thomas, Elizabeth ; Mujais, Salim ; Staskin, David ; Cline, Kevin ; Rovner, Eric ; Owens-Grillo, Janet

PURPOSE:

The efficacy and safety of vibegron, a β₃-adrenergic receptor agonist, was assessed among men with symptoms of overactive bladder (OAB) receiving pharmacologic treatment for benign prostatic hyperplasia (BPH) in a phase 3 randomized controlled trial.

MATERIALS AND METHODS:

Men ≥ 45 years with OAB symptoms and BPH, treated with α-blocker with/without 5α-reductase inhibitors, were randomized 1:1 to vibegron or placebo for 24 weeks. Coprimary end points were change from baseline at week 12 in mean daily micturitions and urgency episodes. Secondary end points were change from baseline at week 12 in mean nightly nocturia and daily urge urinary incontinence episodes, International Prostate Symptom Score‒storage score, and volume voided per micturition. Safety was evaluated via adverse events (AEs).

RESULTS:

Of 1105 participants randomized, 965 (87.3%) completed the trial. At week 12, vibegron was associated with significant reductions vs placebo in daily micturitions (least squares mean difference [95% CI], -0.74 [-1.02, -0.46]; P < .0001) and urgency episodes (-0.95 [-1.37, -0.54]; P < .0001). Vibegron was also associated with significant improvements vs placebo at week 12 in nocturia episodes (least squares mean difference, -0.22 [-0.36, -0.09]; P = .002), urge urinary incontinence episodes (-0.80 [-1.33, -0.27]; P = .003), International Prostate Symptom Score‒storage scores (-0.9 [-1.2, -0.6]; P < .0001), and volume voided (15.07 mL [9.13-21.02]; P < .0001). AE rates were similar in vibegron (45.0%) and placebo (39.0%) arms; AEs occurring in ≥ 2% of participants were hypertension (9.0% vs 8.3%), COVID-19 (4.0% vs 3.1%), UTI (2.5% vs 2.2%), and hematuria (2.0% vs 2.5%).

CONCLUSIONS:

In this trial, vibegron met all primary and secondary end points and was safe and well tolerated in men with OAB symptoms and pharmacologically treated BPH.

2024-07-01·Heliyon

Pantothenate kinase: A promising therapeutic target against pathogenic Clostridium species

Article

作者: Hasnat, Soharth ; Mahbub, M Murshida ; Hoque, M. Nazmul ; Shahinuzzaman, A.D.A. ; Sakif, Tahsin Islam ; Islam, Tofazzal

Current treatment of clostridial infections includes broad-spectrum antibiotics and antitoxins, yet antitoxins are ineffective against all Clostridiumspecies. Moreover, rising antimicrobial resistance (AMR) threatens treatment effectiveness and public health. This study therefore aimed to discover a common drug target for four pathogenic clostridial species, Clostridium botulinum, C. difficile, C. tetani, and C. perfringens through an in-silico core genomic approach. Using four reference genomes of C. botulinum, C. difficile, C. tetani, and C. perfringens, we identified 1484 core genomic proteins (371/genome) and screened them for potential drug targets. Through a subtractive approach, four core proteins were finally identified as drug targets, represented by type III pantothenate kinase (CoaX) and, selected for further analyses. Interestingly, the CoaX is involved in the phosphorylation of pantothenate (vitamin B5), which is a critical precursor for coenzyme A (CoA) biosynthesis. Investigation of druggability analysis on the identified drug target reinforces CoaX as a promising novel drug target for the selected Clostridium species. During the molecular screening of 1201 compounds, a known agonist drug compound (Vibegron) showed strong inhibitory activity against targeted clostridial CoaX. Additionally, we identified tazobactam, a beta-lactamase inhibitor, as effective against the newly proposed target, CoaX. Therefore, identifying CoaX as a single drug target effective against all four clostridial pathogens presents a valuable opportunity to develop a cost-effective treatment for multispecies clostridial infections.

51

项与维贝格龙相关的新闻（医药）

2024-07-18

·Pharmaceutical Technology

MHRA approves Pierre Fabre’s vibegron to treat OAB

The asset is indicated for the treatment of overactive bladder syndrome symptoms in adult patients. Credit: New Africa / Shutterstock. The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pierre Fabre’s vibegron (Obgemsa) to treat overactive bladder (OAB) syndrome symptoms in adults. Symptoms include urgency, high urinary frequency and incontinence. A beta 3 adrenergic receptor agonist, vibegron functions as a bladder muscle relaxant to ease the bladder muscle activity. The recommended daily dose is a 75mg film-coated tablet. The approval is backed by data from the Phase III EMPOWUR clinical trial, which assessed it for 12 weeks in 1,515 OAB patients. See Also: Conflict means millions of children are missing vaccinations, UN says Moderna and Mitsubishi Tanabe link on mRNA vaccines in Japan Participants received a daily dose of either placebo, vibegron 75mg or an active control. Vibegron significantly reduced daily urination and incontinence episodes versus placebo, with improvements observed within two weeks and sustained over the treatment period. Patients on vibegron reported side effects such as headaches, diarrhoea, constipation, nausea, urinary tract infections and increased post-void residual urine volume. The MHRA assures ongoing monitoring of vibegron’s safety and efficacy and encourages reporting of any side effects through the Yellow Card scheme. The MHRA has also approved AstraZeneca ’s capivasertib (Truqap) for advanced HR-positive, HER2-negative breast cancer with specific genetic abnormalities unresponsive to other treatments. Capivasertib, an AKT inhibitor, impedes cancer cell proliferation and is administered orally alongside fulvestrant, a hormonal therapy. The approval was supported by a clinical trial involving 708 patients, with a subset of 289 patients exhibiting the targeted genetic mutations. In clinical studies, capivasertib-treated individuals had an average of 7.3 months during which their cancer did not progress, compared to 3.1 months for placebo-treated patients. High blood sugar, diarrhoea, rash and other skin drug responses, urinary tract infection, low blood haemoglobin levels, appetite loss, nausea, vomiting, mouth sores or ulcers with gum inflammation, itching and fatigue are possible side effects of the medication.

临床结果临床3期上市批准

2024-07-17

·Pharmaceutical Technology

Upperton gains MHRA approval for manufacturing in Nottingham

Upperton Pharma will move from R&D to GMP production and commercialisation on a single site. Credit: Upperton Limited. UK-based contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its facility in Nottingham. The approval, granted following an MHRA inspection, marks the expansion of the company’s capabilities at this newly commissioned 50,000ft² development and GMP [good manufacturing practices] facility. Upperton Pharma completed the construction, commissioning, validation and approval process for the unit within 18 months. The CDMO will develop oral, nasal and pulmonary drug assets, offering Phase I, II, and III clinical supplies. Upperton Pharma will move from research and development (R&D) to GMP production and commercialisation on a single site. See Also: MHRA approves Pierre Fabre’s vibegron to treat OAB Rusan Pharma’s API Plant in Ankleshwar Receives US FDA GMP Approval The facility’s recent investment in large-scale process equipment, including a Gerteis mini-pactor, a GEA post-hoist blender, an O’Hara M50 tablet coating system and a ZANASI 40 capsule filler, will aid Upperton Pharma in handling batch sizes up to 250kg. Its capability covers a broad range of dosage forms such as liquids, solids, semi-solids and inhaled pharmaceuticals, including potent molecules and controlled drugs. With 24 years of experience, Upperton Pharma provides early drug development solutions to clients worldwide. The company has formulation and analytical development laboratories, GMP manufacturing and quality control testing capabilities. It is licensed by the MHRA for manufacturing clinical trial material supplies. It also has expertise in spray drying, a technique used to address challenges with poorly soluble molecules, and as a particle engineering technology for targeted pulmonary and nasal drug product deposition. Upperton Pharma Solutions CEO Nikki Whitfield stated: “We are absolutely delighted to achieve this milestone. “We have been conducting manufacturing scale-up activities since the start of the year following the installation of the larger-scale solid oral dosage form process trains and this gives the green light for our GMP facility to support clients right through to late-phase clinical manufacture and product registration.”

上市批准

2024-07-16

·Pharmaceutical Technology

SII and Oxford University’s malaria vax launched in Côte d’Ivoire

SII has already produced 25 million doses and aims to further increase production to 100 million doses per year. Credit: Diana Polekhina on Unsplash. The R21/Matrix-M malaria vaccine, co-developed by the Serum Institute of India (SII) and the University of Oxford, has been launched in Côte d’Ivoire, making it the first country to administer the shot. The new R21/Matrix-M malaria vaccine utilises Novavax ’s Matrix-M adjuvant technology. Following extensive clinical trials that showcased both its tolerance and safety and found only minor side effects such as injection site pain and fever, R21/Matrix-M was awarded prequalification status by the World Health Organization (WHO) in December 2023. This certification followed a stringent regulatory review process. SII has already produced 25 million doses of the vaccine and aims to further increase production to 100 million doses annually. See Also: MHRA approves Pierre Fabre’s vibegron to treat OAB Rusan Pharma’s API Plant in Ankleshwar Receives US FDA GMP Approval In line with its mission to provide vaccines affordably and at scale, SII is offering R21/Matrix-M at under $4 per dose. This production capability is pivotal for rapid and large-scale manufacturing, essential for curbing disease spread and safeguarding those vaccinated. Côte d’Ivoire has received an initial batch of 656,600 doses and is targeting the immunisation of 250,000 children aged up to 23 months in 16 regions. Nigeria, Ghana, Burkina Faso and the Central African Republic have also authorised the use of the R21/Matrix-M vaccine. It stands as the second malaria vaccine available in sub-Saharan Africa after RTS,S. Oxford University’s Jenner Institute director, Professor Adrian Hill stated: “The roll-out of the R21/Matrix-M malaria vaccine marks the start of a new era in malaria control interventions with the high efficacy vaccine now accessible at a modest price and very large scale to many countries in greatest need.” Global health organisations such as WHO, Gavi [the Global Alliance for Vaccine and Immunization], UNICEF [the United Nations Childrens Fund] and the Global Fund are collaborating with countries to integrate the vaccine into comprehensive malaria control and prevention strategies. With Gavi’s support, 15 African nations are set to introduce malaria vaccines. Plans are underway to immunise 6.6 million children with the malaria vaccine during 2024 and 2025.

上市批准疫苗突破性疗法临床研究

100 项与维贝格龙相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10433	维贝格龙	G04BD	DB14895

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
膀胱过度活动症综合征	欧盟	Pierre Fabre Médicament SAS	2024-06-28
膀胱过度活动症综合征	冰岛	Pierre Fabre Médicament SAS	2024-06-28
膀胱过度活动症综合征	列支敦士登	Pierre Fabre Médicament SAS	2024-06-28
膀胱过度活动症综合征	挪威	Pierre Fabre Médicament SAS	2024-06-28
尿频	美国	Urovant Sciences, Inc.	2020-12-23
急迫性尿失禁	美国	Urovant Sciences, Inc.	2020-12-23
膀胱过度活动症	日本	KYORIN Pharmaceutical Co., Ltd.	2018-09-21
膀胱过度活动症	日本	Kissei Pharmaceutical Co., Ltd.	2018-09-21

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
神经源性逼尿肌过度活动	临床3期	美国	Urovant Sciences Ltd.	2022-10-12
前列腺增生症	临床3期	美国	Urovant Sciences Ltd.	2019-03-26
前列腺增生症	临床3期	比利时	Urovant Sciences Ltd.	2019-03-26
前列腺增生症	临床3期	加拿大	Urovant Sciences Ltd.	2019-03-26
前列腺增生症	临床3期	匈牙利	Urovant Sciences Ltd.	2019-03-26
前列腺增生症	临床3期	立陶宛	Urovant Sciences Ltd.	2019-03-26
前列腺增生症	临床3期	波兰	Urovant Sciences Ltd.	2019-03-26
前列腺增生症	临床3期	葡萄牙	Urovant Sciences Ltd.	2019-03-26
前列腺增生症	临床3期	西班牙	Urovant Sciences Ltd.	2019-03-26
疼痛	临床2期	美国	Urovant Sciences Ltd.	2019-01-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04103450 (CTgov)	临床3期	前列腺增生症 \| 膀胱过度活动症	276	Vibegron (52-Week Vibegron Group)	壓願廠築積簾蓋壓襯觸(鹹獵齋獵獵顧鑰膚蓋積) = 憲製鹽鏇壓鑰願糧衊夢築積廠繭糧衊構襯淵膚 (餘蓋餘網顧襯蓋憲膚遞, 繭簾醖鏇鹽淵醖鹽憲簾 ~ 襯廠襯蓋齋鑰窪膚簾範) 更多	-	2024-08-21
				Vibegron (28-Week Vibegron Group)	壓願廠築積簾蓋壓襯觸(鹹獵齋獵獵顧鑰膚蓋積) = 構淵襯鏇選衊襯顧窪觸築積廠繭糧衊構襯淵膚 (餘蓋餘網顧襯蓋憲膚遞, 衊壓醖鹹鹽壓網蓋構壓 ~ 餘觸夢製繭積衊壓簾繭) 更多
NCT03902080 (URO-901-3005, CTgov)	临床3期	前列腺增生症 \| 膀胱过度活动症	1,105	Placebo	廠簾鬱製糧鏇繭繭衊醖(鏇夢選選鹽遞齋醖鏇衊) = 願壓構遞網遞蓋鹹齋鑰網糧鏇鹽襯構糧範鏇觸 (廠獵餘襯獵艱夢範鏇衊, 鏇窪憲糧鑰壓齋遞鏇鏇 ~ 獵鬱構鹹繭築範觸廠顧) 更多	-	2024-08-07
NCT03902080 (URO-901-3005, PRNewswire) 人工标引	临床3期	膀胱过度活动症	-	Vibegron 75mg (GEMTESA)	網鏇廠範獵壓鑰獵醖壓(簾遞憲願窪願鹽簾廠網) = 夢獵糧範網鹹餘憲願鹽廠選鹽醖網淵蓋鹹願繭 (範窪鬱窪鹽鹽範廠觸繭, 0.109) 更多	积极	2024-05-07
NCT03492281 (EMPOWUR, Pubmed \| J Comp Eff Res)	临床3期	膀胱过度活动症	-	Vibegron	網觸夢築鏇鏇醖襯齋構(鏇繭糧鏇願簾網鏇鏇鹽) = 窪蓋廠簾網壓鏇衊觸糧廠齋鏇鬱衊遞製範鏇簾 (夢築積製鏇鬱鬱艱簾夢 ) 更多	积极	2023-09-01
NCT03492281 (EMPOWUR, Pubmed) 人工标引	临床3期	膀胱过度活动症	922	Vibegron	膚獵鹹壓顧構鏇廠範艱(繭願範鬱獵醖憲顧觸範): difference = -0.5 (95% CI, -0.8 ~ -0.2) 更多	积极	2022-11-21
				Placebo
AUA2022	N/A	膀胱功能障碍 \| 脊柱裂辅助	19	Vibegron	願繭醖窪齋願願築艱淵(鏇範憲醖鬱網膚簾艱簾) = 鹹窪構顧憲繭壓積憲遞窪餘顧鹹艱鏇餘廠製鏇 (獵衊鹹糧繭衊遞積願壓 )	-	2022-05-01
				Antimuscarinic therapy	願繭醖窪齋願願築艱淵(鏇範憲醖鬱網膚簾艱簾) = 夢製衊遞憲觸製獵衊襯窪餘顧鹹艱鏇餘廠製鏇 (獵衊鹹糧繭衊遞積願壓 )
NCT03492281 (EMPOWUR, Pubmed \| Adv Ther) 人工标引	临床3期	膀胱过度活动症	-	vibegron	獵鬱選蓋窪範願壓網醖(範淵網鬱顧鹽築鏇繭膚) = 積遞艱廠網簾膚壓襯憲衊簾膚網簾範繭糧構壓 (糧繭積糧淵壓淵鬱繭鏇 ) 更多	积极	2021-12-18
				Placebo	獵鬱選蓋窪範願壓網醖(範淵網鬱顧鹽築鏇繭膚) = 襯夢築夢願淵選鹹鑰遞衊簾膚網簾範繭糧構壓 (糧繭積糧淵壓淵鬱繭鏇 ) 更多
NCT03806127 (CTgov)	临床2期	肠易激综合征	222	Placebo (Placebo)	襯膚繭網獵構選廠窪選(鹹壓衊艱壓醖艱鑰構觸) = 顧憲夢遞觸齋鏇網襯夢壓襯膚範繭餘壓醖網遞 (觸襯衊鑰鹽選餘衊窪簾, 壓壓襯淵簾選願蓋艱築 ~ 齋範夢繭獵築憲齋齋築) 更多	-	2021-07-30
				Vibegron (Vibegron 75 mg)	襯膚繭網獵構選廠窪選(鹹壓衊艱壓醖艱鑰構觸) = 膚蓋窪壓願鏇襯鹹積繭壓襯膚範繭餘壓醖網遞 (觸襯衊鑰鹽選餘衊窪簾, 壓艱選積鬱齋鬱衊鹽蓋 ~ 鹽積糧淵鬱衊獵壓顧鹹) 更多
NCT03583372 (Pubmed \| J Urol) 人工标引	临床3期	膀胱过度活动症	506	vibegron	蓋鹹願淵餘餘廠窪廠鬱(積鬱廠網膚衊鬱齋製網) = 鑰蓋窪選觸鑰蓋鑰構構衊齋遞積構襯憲鏇鑰願 (餘願顧願襯衊觸範獵範 ) 更多	积极	2021-05-01
				tolterodine	齋淵廠壓窪鑰鹽淵獵鹽(鑰鑰餘範選壓醖鏇糧簾) = 構齋鹽範鬱獵襯範選艱獵顧鹽夢餘艱襯醖獵襯 (襯繭築築範膚憲醖夢廠 ) 更多
NCT03492281 (EMPOWUR, CTgov)	临床3期	膀胱过度活动症	1,530	placebo (Placebo)	襯鏇餘壓繭壓選廠糧遞(網選餘壓膚觸廠鹹築願) = 窪鹹鏇廠蓋觸夢廠淵構廠衊憲鑰廠構選鹹鏇積 (膚窪簾築遞製餘夢遞壓, 醖繭構遞廠製選廠鹹蓋 ~ 築觸積顧壓鑰顧網窪網) 更多	-	2021-03-04
				Vibegron (Vibegron 75 mg)	襯鏇餘壓繭壓選廠糧遞(網選餘壓膚觸廠鹹築願) = 築醖醖鹹構壓衊膚鏇鬱廠衊憲鑰廠構選鹹鏇積 (膚窪簾築遞製餘夢遞壓, 醖糧艱構網鹽餘積積繭 ~ 壓艱蓋觸壓遞夢齋選築) 更多